Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker
Objective: We aimed to investigate the utility of alpha-synuclein (α-SYN) immunoreactivity from gastric and colonic mucosal tissues obtained by routine endoscopy to detect Parkinson's disease…Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2
Objective: Using neuromelanin (NM)-MRI, we analyzed whether disease severity and MF is associated with the degree of dopaminergic neuronal degeneration in the substantial nigra compacta…Different patterns of spontaneous brain activity between tremor-dominant and postural instability/gait difficulty subtypes of Parkinson’s disease: A resting-state fMRI study
Objective: This study aimed at investigating the subtype-specific patterns of spontaneous brain activity in PD. Background: Postural instability/gait difficulty (PIGD) and tremor-dominant (TD) subtypes of…Mitochondrial response precedes intracellular accumulation of α-synuclein in Parkinson’s disease
Objective: To investigate the expression of mitochondrial COX-IV during the progression of Parkinson's disease. Background: Parkinson's disease (PD) is a neurodegenerative disease characterized by the…The contribution of the subthalamic nucleus in gait initiation of subjects with Parkinson’s disease
Objective: We investigated the contribution of the subthalamic nucleus (STN) in gait initiation of subjects with Parkinson's disease (PD). Background: Gait initiation is the transient…Alpha synuclein and crystallin expression in human lens in Parkinson’s disease
Objective: To determine the Protein Profile of cataract lenses in Parkinson's disease (PD). Background: Protein accumulation, mainly αB-crystallin, in the lens causes cataract. PD is…Investigating the role of Parkin in mitigating oxidative stress
Objective: We are investigating the ability of Parkin protein to protect cells from oxidative stress (OS) and the mechanisms that underlie this function. We hypothesize…Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)
Objective: Determine the minimum MDS-UPDRS Part III improvement needed to convert a patient from the morning OFF state to a full ON with APL-130277. Background:…Alterations in 14-3-3 protein phosphorylation as a biomarker for neurodegeneration
Objective: To examine whether 14-3-3 phosphorylation is altered in Parkinson's disease and other neurodegenerative disorders. Background: 14-3-3 proteins are a highly conserved family of proteins…Pathophysiological mechanisms of bone mass loss for osteoporosis prevalence in Parkinson’s disease
Objective: Quantify the impact of osteoporosis in Parkinson's disease to know factors that caused bone loss. Background: Parkinson´s disease (PD) and osteoporosis are two conditions…
- « Previous Page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- …
- 207
- Next Page »